Stocklytics Platform
Asset logo for symbol RVNC
Revance Therapeutics
RVNC63
$3.09arrow_drop_up0.32%$0.01
Penny Stock
Asset logo for symbol RVNC
RVNC63

$3.09

arrow_drop_up0.32%

Income Statement (RVNC)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$29.88M-$31.79M-$44.26M-$50.30M-$41.86M
EBITDA-$28.63M-$30.36M-$42.28M-$48.88M-$39.74M
gross Profit$42.24M$46.32M$35.04M$50.90M$37.36M
NET Income-$35.11M-$37.47M-$53.15M-$55.69M-$141.17M
total Revenue$59.87M$65.38M$51.93M$69.79M$56.77M

Balance Sheet (RVNC)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt$424.86M$409.90M$342.61M$340.55M$308.58M
stockholders Equity-$163.03M-$129.73M-$98.67M-$151.60M-$106.20M
total Assets$461.56M$494.79M$508.11M$478.45M$532.48M
total Debt$483.44M$491.63M$475.77M$478.43M$487.89M
total Liabilities$624.59M$624.53M$606.79M$630.05M$638.68M

Cash Flow (RVNC)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$6.08M-$3.41M$92.82M-$1.62M$37.46M
free Cash Flow-$41.15M-$41.59M-$67.65M-$44.51M-$55.46M
investing Cash Flow-----
operating Cash Flow-$41.09M-$41.12M-$65.93M-$42.73M-$50.96M

Revance Therapeutics (RVNC) Financials

Revance Therapeutics Inc (RVNC) is a biotechnology company that specializes in the development and commercialization of novel aesthetic and therapeutic products. The company's financial performance is reflected in its income statement, which details its revenue, expenses, and net income from stockholders. In the latest reported period, Revance Therapeutics Inc generated total revenue of $22.5 million, representing a significant increase compared to the previous year. The company's gross profit was $14.3 million, indicating a healthy margin on its products and services. However, after accounting for operating expenses, the company reported an EBIT loss of $78.9 million.
Revance Therapeutics Inc's balance sheet shows a strong financial position with total assets of $604.8 million. The company has a significant amount of cash equivalents, which provide liquidity and flexibility in its operations. Additionally, Revance Therapeutics Inc has a favorable stockholders equity of $285.6 million, indicating a solid base of shareholder support. However, the company also has total debt of $223.4 million, which should be carefully managed to avoid excessive leverage.
In terms of cash flow, Revance Therapeutics Inc has been focused on financing its operations and investing in research and development initiatives. The company has a positive operating cash flow, indicating that its core business is generating cash. However, the company has been utilizing its financing cash flow to meet its capital requirements and fund its growth strategies. The investing cash flow reflects the company's investments in property, plant, and equipment, as well as acquisitions of intangible assets. Overall, Revance Therapeutics Inc strives to maintain a balanced cash flow to support its long-term growth and profitability.
add Revance Therapeutics  to watchlist

Keep an eye on Revance Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level